23 September 2020 - This time it is for polatuzumab vedotin (Polivy) for patients with non-Hodgkin's lymphoma.

Polatuzumab vedotin, when used in combination with rituximab and bendamustine hydrochloride, is recommended as an option for the treatment of adults with relapsed or refractory diffuse large B‑cell lymphoma who cannot have a haematopoietic stem cell transplant. 

Polatuzumab is recommended only if Roche provides polatuzumab vedotin according to the commercial arrangement.

Read NICE technology appraisal guidance for polatuzumab vedotin